BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 12243915)

  • 1. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
    Cuzick J; Forbes J; Edwards R; Baum M; Cawthorn S; Coates A; Hamed A; Howell A; Powles T;
    Lancet; 2002 Sep; 360(9336):817-24. PubMed ID: 12243915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
    Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
    J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
    Nelson HD; Smith ME; Griffin JC; Fu R
    Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
    Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
    J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.
    Veronesi U; Maisonneuve P; Costa A; Sacchini V; Maltoni C; Robertson C; Rotmensz N; Boyle P
    Lancet; 1998 Jul; 352(9122):93-7. PubMed ID: 9672273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).
    Mignotte H; Lasset C; Bonadona V; Lesur A; Luporsi E; Rodier JF; Cutuli B; Lasry S; Mauriac L; Granon C; Kerr C; Giard S; Hill C; de Lafontan B; de Gislain C; D'Anjou J; Fondrinier E; Lefeuvre C; Parache RM; Chauvin F
    Int J Cancer; 1998 May; 76(3):325-30. PubMed ID: 9579567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of the main outcomes in breast-cancer prevention trials.
    Cuzick J; Powles T; Veronesi U; Forbes J; Edwards R; Ashley S; Boyle P
    Lancet; 2003 Jan; 361(9354):296-300. PubMed ID: 12559863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
    Cuzick J; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A; Forbes JF;
    Lancet Oncol; 2015 Jan; 16(1):67-75. PubMed ID: 25497694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.
    Veronesi U; Maisonneuve P; Rotmensz N; Costa A; Sacchini V; Travaglini R; D'Aiuto G; Lovison F; Gucciardo G; Muraca MG; Pizzichetta MA; Conforti S; Decensi A; Robertson C; Boyle P;
    J Natl Cancer Inst; 2003 Jan; 95(2):160-5. PubMed ID: 12529349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
    Cuzick J; Sestak I; Forbes JF; Dowsett M; Cawthorn S; Mansel RE; Loibl S; Bonanni B; Evans DG; Howell A;
    Lancet; 2020 Jan; 395(10218):117-122. PubMed ID: 31839281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries.
    Jones ME; van Leeuwen FE; Hoogendoorn WE; Mourits MJ; Hollema H; van Boven H; Press MF; Bernstein L; Swerdlow AJ
    Breast Cancer Res; 2012 Jun; 14(3):R91. PubMed ID: 22691381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
    Cuzick J; Warwick J; Pinney E; Duffy SW; Cawthorn S; Howell A; Forbes JF; Warren RM
    J Natl Cancer Inst; 2011 May; 103(9):744-52. PubMed ID: 21483019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen.
    Bergman L; Beelen ML; Gallee MP; Hollema H; Benraadt J; van Leeuwen FE
    Lancet; 2000 Sep; 356(9233):881-7. PubMed ID: 11036892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.
    Powles T; Eeles R; Ashley S; Easton D; Chang J; Dowsett M; Tidy A; Viggers J; Davey J
    Lancet; 1998 Jul; 352(9122):98-101. PubMed ID: 9672274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan.
    Matsuyama Y; Tominaga T; Nomura Y; Koyama H; Kimura M; Sano M; Miura S; Takashima S; Mitsuyama S; Ueo H; Ohashi Y
    Ann Oncol; 2000 Dec; 11(12):1537-43. PubMed ID: 11205460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.